


Cantargia

Healthcare
Sweden


KEY DATA

Stock country	Sweden
Bloomberg	CANTA SS
Reuters	CANTA.ST
Share price (close)	SEK 53.40
Free Float	80%
Market cap. (bn)	EUR 0.47/SEK 4.86
Website	http://cantargia.com/
Next report date	12 Nov 2020

PERFORMANCE



VALUATION APPROACH



Source: Nordea estimates

ESTIMATE CHANGES

Year	2020E	2021E	2022E
Sales	0%	144%	-100%
EBIT (adj)	0%	174%	-137%

Source: Nordea estimates

Nordea Markets - Analysts

Klas Pyk
Analyst

More news ahead

Over the past few weeks, Cantargia has presented positive interim data from the ongoing CANFOUR trial, which has significantly strengthened our conviction in a successful outcome of ph IIa. The full readout is expected within the coming months, but the company has, on the back of the recent findings, already started planning to advance the development of CAN04 in both NSCLC and PDAC. During Q4, we expect Novartis to present data from its ongoing ph III trial for Canakinumab, which will provide further insight into targeting the IL-1 system for cancer treatment. We increase our DCF-based fair value range to SEK 48-54 (24-27) per share and see several valuation triggers ahead.

Further positive interim data from CAN04

Following the interim data from CANFOUR announced in December last year, Cantargia has published further positive findings from the ongoing trial over the past few weeks. The data shows that the response rate in the evaluable patients was meaningfully higher for the combination treatment with CAN04 compared to the investigated chemotherapies alone. The ongoing pandemic has had a negative impact on recruitment for the NSCLC arm of the trial and it will therefore not proceed as previously planned. On the back of the recent positive findings, this is not deemed necessary, however, and Cantargia has already started planning to advance the development in both NSCLC and PDAC.

We increase our conviction and raise our valuation range

The positive interim data has significantly strengthened our conviction in a positive outcome of ph IIa and subsequently the likelihood of CAN04 eventually being commercialised. Thus, we increase our risk adjustment to 18.5-35% (from 9-12%), depending on indication, and subsequently increase our fair value range to SEK 48-54 (24-27) per share. To estimate the earnings potential, we use royalty-based revenue that assumes that Cantargia is able to find a strategic partner in 2021. We see several valuation triggers for the share ahead, including the full readout from CANFOUR, the upcoming results from the Novartis Canakinumab ph III trial and a potential partnership agreement.

SUMMARY TABLE - KEY FIGURES

SEKm	2016	2017	2018	2019	2020E	2021E	2022E
Total revenue	0	0	0	0	0	2,850	0
EBITDA (adj)	-45	-60	-93	-112	-191	2,645	-68
EBIT (adj)	-45	-60	-93	-112	-191	2,645	-68
EBIT (adj) margin	n.m.	n.m.	n.m.	n.m.	n.m.	92.8%	n.m.
EPS (adj, SEK)	-2.14	-1.28	-1.38	-1.52	-2.08	22.72	-0.27
EPS (adj) growth	-67.4%	39.9%	-7.3%	-10.5%	-36.4%	1,194.3%	-101.2%
DPS (ord, SEK)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EV/Sales	n.a.	n.m.	n.m.	n.m.	n.m.	0.9	n.m.
EV/EBIT (adj)	n.a.	n.m.	n.m.	n.m.	n.m.	0.9	n.m.
P/E (adj)	n.a.	n.m.	n.m.	n.m.	n.m.	2.4	n.m.
P/BV	n.a.	1.2	6.1	10.3	13.4	2.0	2.0
Dividend yield (ord)	n.a.	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
FCF Yield bef A&D, lease	n.a.	-13.7%	-11.1%	-7.6%	-4.3%	42.5%	-0.5%
Net debt	-35	-270	-167	-150	-349	-2,416	-2,392
Net debt/EBITDA	n.m.	n.m.	n.m.	n.m.	n.m.	-0.9	n.m.
ROIC after tax	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.

Source: Company data and Nordea estimates

Factors to consider


Cantargia is a biotech company active in the field of immuno-oncology, specialising in antibody-based cancer treatment. Its antibody candidate CAN04 has a dual mechanism of action, as it fights cancer by activating the immune system and by blocking signals that lead to tumour growth. CAN04 is aimed for a combination treatment together with chemotherapy targeting non-small cell lung cancer (NSCLC) and pancreatic cancer (PDAC), with expected readout in the coming months. The ph II interim results, most recently updated in September and October 2020, however, have shown promising response rates, indicating the potential of the ongoing trial. Cantargia's approach has also been validated by a similar concept owned by Novartis, which will provide ph III data during Q4 2020.

Cantargia was founded in 2009, based on research from Lund University. The company's main project, CAN04, currently in ph IIa, is aimed for a combination treatment together with chemotherapy targeting non-small cell lung cancer (NSCLC) and pancreatic cancer (PDAC). Lung cancer is the form of cancer that causes the largest number of deaths and non-small cell lung cancer is the most common form of the disease. Pancreatic cancer is very hard to cure, and few effective treatments have so far been developed. In parallel with CAN04, Cantargia is developing CAN10, focusing on two serious autoimmune/inflammatory diseases, systemic sclerosis and myocarditis.

In ph IIa, CAN04 is being evaluated as monotherapy and in combination with chemotherapy. Cantargia plans to present the ph IIa results for CAN04 in the coming months.

Ph IIa results are expected in the coming months

CANTARGIA'S PROJECT PORTFOLIO



Source: Cantargia

Encouraging interim ph IIa results

Cantargia has presented positive interim data from the ongoing ph IIa trial on three occasions. In December 2019, it presented positive interim data from ten patients (seven with pancreatic cancer and three with metastatic non-small cell lung cancer) who had been evaluated. The interim data shows that four out of seven evaluated patients with metastatic pancreatic cancer (PDAC) demonstrated partial response to the treatment. This should be compared to the historical response rate of the investigated chemotherapies, which is 23% in PDAC, indicating that the response rate increases with the addition of CAN04. Three NSCLC patients were also evaluated, of whom one had a confirmed complete response and one a partial response.

CAN04: INTERIM PH IIA RESULTS, DECEMBER 2019


	Evaluable	Complete/Partial Response	Stable Disease	Progressive Disease
PDAC	7	4 (54%)	0	3 (43%)
- Historical, PDAC, %		23%	27%	20%
NSCLC	3	2 (67%)	1 (33%)	0
- Historical, NSCLC, %		22-28%	18%	40%

Source: Company data and Nordea

On 23 September 2020, Cantargia announced updated interim results for NSCLC. At the time, 13 patients had started the therapy, of which nine were evaluable. The data showed that tumour burden decreased in all nine evaluable patients, and in six of these patients, the decrease was large enough to be defined as a response (of which one had a complete response), corresponding to a response rate of 67%, compared to the historical response rates of the investigated chemotherapies of 22-28%, again indicating that response rates increase with the addition of CAN04.

Owing to the ongoing pandemic, recruitment to the NSCLC arm of the CANFOUR trial has been slower than expected and it will not proceed as initially planned. According to Cantargia, however, enough data has already been generated to advance the development of CAN04 in NSCLC.


CAN04: INTERIM PH IIA RESULTS, NSCLC, SEPTEMBER 2020



Source: Cantargia

On 8 October 2020, Cantargia provided further interim data for PDAC. At the time, 31 patients had started the therapy, of which 20 were evaluable. Partial responses had been documented in eight of the evaluable patients, corresponding to a response rate of 40%, meaningfully higher than the 23% historical response rate for the investigated chemotherapies.

CAN04: INTERM PH IIA RESULTS, PDAC, OCTOBER 2020



Source: Company data and Nordea estimates


Cantargia's technology has been validated by Novartis

CAN04 targets the IL1RAP molecule and fights cancer through a dual mechanism of action: both by activating the immune system and simultaneously blocking signals that drive tumour growth. IL1RAP is expressed in tumours from several forms of cancer,

which means that the substance can potentially be used for treatment of additional indications to its current main targets, NSCLC and PDAC.


Cantargia's technology is based on the IL-1 system. IL-1, which appear in two forms, IL-1 α and IL-1 β , circulates in the blood and it plays an essential role in the body's immune defence by simulating the immune cells. IL-1 binds to receptors on the surface of the cells to produce other signalling substances. Some of the receptors are IL1RAP, which transmits signals that are important for tumour inflammation and progression. CAN04 is based on the concept of blocking the target molecule IL1RAP and thereby preventing both IL-1 α and IL-1 β from transmitting inflammatory signals that drive tumour growth. At the same time, CAN04 stimulates the body's immune system, which sends natural killer (NK) cells to attack the tumour.

CAN04: TWO MODES OF ACTION (1)



Source: Cantargia

CAN04: TWO MODES OF ACTION (2)



Source: Cantargia

A similar concept has been applied by Novartis through its Canakinumab. CAN04, however, differs from Canakinumab, as the latter is an antibody that binds one of the two ligands, IL-1 β , while CAN04 binds the common signalling receptor, IL1RAP, and thus counteracts both ligands, implying a potentially broader mechanism of action.

In 2017, Novartis announced primary data from its Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS), one of the company's largest studies ever conducted, spanning six years and consisting of more than 10,000 enrolled patients. The study met its primary endpoints by showing that Canakinumab in combination with standard treatment reduces cardiovascular risk in patients with heart attack history and inflammatory atherosclerosis.

More intriguing from Cantargia's point of view, however, were the results from the pre-planned oncology safety analyses, which revealed a 77% reduction in cancer mortality and a 67% reduction in lung cancer incidence. According to Novartis, this was the first ph III trial confirming the preclinical hypothesis that inhibition of IL-1 β reduces cancer incidence and mortality.

In response to the encouraging CANTOS results, Novartis initiated a number of ph III studies with Canakinumab in NSCLC, with expected readout in Q4 2020, which will provide further insights into targeting the IL-1 system for cancer treatment. In Novartis' Investor Oncology Pipeline Update presentation from June 2020, Canakinumab was a key element for the company's future growth.

CANAKINUMA: NOVARTIS' FOCUS AREAS FOR DRIVING FUTURE GROWTH

Four therapeutic modalities to drive future growth


Targeted Therapies



Select pipeline assets and opportunities


Kisqali® in adjuvant BC
Alpelisib in
 ▪ HER2+ advanced BC
 ▪ TNBC
 ▪ Head & neck
 ▪ Ovarian cancer
 ▪ PROS
Adakveo® in sickle cell disease
Tabrecta™ in NSCLC, single agent and combinations
Jakavi® in GvHD, and combinations (platform) in MF
Asciminib in CML
LXH254 in RAS/RAF mutant melanomas and lung cancer
TNO155 in solid tumors

Immunotherapies




Canakinumab in
 ▪ adjuvant NSCLC
 ▪ 1st line NSCLC
 ▪ 2nd line NSCLC
Spartalizumab+Tafinlar®+Mekinist® in metastatic melanoma
Spartalizumab combinations (platform) in metastatic melanoma
Spartalizumab+LAG525+carboplatin in TNBC
Spartalizumab+Tabrecta™ in NSCLC
MBG453 in MDS and AML
VPM087 in CRC and RCC
NIS793 in solid tumors

Radioligand



Lutathera® in 1st line grade 2/3 advanced GEP-NET
¹⁷⁷Lu-PSMA-617 in prostate cancer
¹⁷⁷Lu-PSMA-R2 in prostate cancer
¹⁷⁷Lu-NeoB in multiple solid tumors
¹⁷⁷Lu-FF58 in glioblastoma

Cell & Gene



Kymriah® in
 ▪ r/r DLBCL after 1st relapse
 ▪ r/r follicular lymphoma
 ▪ r/r adult ALL
 ▪ combinations (pembrolizumab; ibritinib) in r/r DLBCL
 ▪ pediatric NHL
 ▪ 1st line high risk pediatric and young adult ALL
YTB323 in
 ▪ r/r DLBCL
 ▪ r/r CLL combination with ibritinib
PHE885 in r/r MM
Other targets: BCMA&CD19, CD22&CD19, CD123, EGFRvIII

5 Novartis Oncology Pipeline Update | June 15, 2020


NOVARTIS | Reimagining Medicine

Source: Novartis

CANAKINUMAB: LUNG CANCER INCIDENCE

Lung cancer incidence

Dose-dependent effect, 67% relative risk reduction, $P < 0.0001$ (canakinumab 300mg)




Source: Novartis

CANAKINUMAB: LUNG CANCER MORTALITY

Lung cancer mortality

Dose-dependent effect, 77% relative risk reduction, $P = 0.0002$ (canakinumab 300mg)



Source: Novartis

CANAKINUMAB: PH III OVERVIEW

CANOPY: Three Phase 3 studies ongoing with canakinumab in NSCLC, first to read out in Q4 2020

CANakinumab Outcomes in Patients with NSCLC Study

Indication	Patient population	Trial design	Status as of Jun 2020	Planned filing
Adjuvant NSCLC (CANOPY-A)	High-risk Stage II-III	Canakinumab vs. placebo (n=1500 with 1:1 randomization) after post-resection chemotherapy	~40% of patients enrolled	2023
1st line NSCLC (CANOPY-1)	Non-mutated, no prior treatment for metastatic disease or Stage III unresectable	Platinum doublet chemotherapy and pembrolizumab with or without canakinumab (n=600 with 1:1 randomization)	Enrollment completed; interim analysis expected in Q4 2020	2021
2nd line NSCLC (CANOPY-2)	Non-mutated with no more than 2 prior lines of metastatic treatment (PD-1 ± chemo)	Docetaxel with or without canakinumab (n=226 with 1:1 randomization)	Enrollment completed; final analysis expected in 2021	2021
Neoadjuvant NSCLC (CANOPY-N; Phase 2)	Stage IB - IIIA	Canakinumab, canakinumab+pembrolizumab or pembrolizumab (n=110 with 2:2:1 randomization)	First patient enrolled in Q4 2019; ~20% of patients enrolled	Not registrational study

29 Novartis Oncology Pipeline Update | June 15, 2020



Source: Novartis

Estimates and valuation

Provided that the clinical programme is successful, we expect that CAN04 can be commercialised in 2024 at the earliest. We assume that Cantargia will enter into a partnership agreement to commercialise CAN04, including an upfront payment, royalties and milestone payments. We estimate peak sales of SEK ~23,300m (USD ~2.6bn), which we risk-adjust by 18.5-35%, depending on indication, and derive a DCF-based fair valuation range of SEK 48-54 per share.

To estimate the earnings potential, we use a royalty-based revenue model that assumes Cantargia is able to find a strategic partner. The design of such a partnership depends on numerous factors, such as market potential, competition, relative bargaining power and stage of development.

Even though we acknowledge the underlying uncertainty over the timing and structure of a potential partnership agreement, we assume that Cantargia will enter into a partnership agreement in 2021, provided that the CANFOUR ph IIa results are successful. We assume that the partner will take responsibility for the pivotal trials and commercialisation of CAN04.

We only include NSCLC and PDAC in our forecasts and estimate that CAN04 can reach peak revenues of SEK ~23,300m (USD ~2.6bn), on which the partner will pay 15% royalties to Cantargia. Based on the likelihood of approval for similar indications, we risk-adjust the royalties by 35% for NSCLC and 18.5% for PDAC. We also assume that the partner will contribute upfront payments totalling SEK 2,850m and milestone payments of SEK 475m (risk-adjusted to SEK 130m).

REVENUE MODEL: CAN04 SUMMARY

	2020E	2021E	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E	2031E	2032E
Total CAN04 sales, SEKm	-	-	-	-	3,512	5,294	7,801	11,653	16,996	19,578	21,093	22,202	23,321
Total royalties to Cantargia, SEKm	-	-	-	-	525	791	1,165	1,741	2,539	2,924	3,151	3,316	3,483
Total milestones, SEKm	-	2,850	-	475	-	-	-	-	-	-	-	-	-
- of which NSCLC, SEKm	-	1,500	-	250	-	-	-	-	-	-	-	-	-
- of which PDAC, SEKm	-	1,350	-	225	-	-	-	-	-	-	-	-	-
Total revenues, SEKm	-	2,850	-	475	525	791	1,165	1,741	2,539	2,924	3,151	3,316	3,483
Total royalties, risk-adjusted, SEKm	-	-	-	-	144	217	324	500	746	864	932	990	1,047
Total milestones, risk-adjusted, SEKm	-	2,850	-	130	-	-	-	-	-	-	-	-	-
Total revenues, risk-adjusted, SEKm	-	2,850	-	130	144	217	324	500	746	864	932	990	1,047

Source: Nordea estimates

REVENUE MODEL: CAN04, NSCLC

	2020E	2021E	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E	2031E	2032E
US													
Patient volume	-	-	-	-	1,195	1,801	2,413	3,638	4,875	5,512	6,155	6,805	7,460
Price, USD	-	-	-	-	70,000	70,000	70,000	70,000	70,000	70,000	70,000	70,000	70,000
Total sales, USDm	-	-	-	-	84	126	169	255	341	386	431	476	522
Royalty rate, %	-	-	-	-	15%	15%	15%	15%	15%	15%	15%	15%	15%
Royalties to Cantargia, USDm	-	-	-	-	13	19	25	38	51	58	65	71	78
Europe													
Patient volume	-	-	-	-	2,470	3,724	4,990	7,522	10,079	11,396	12,725	14,068	15,423
Price, EUR	-	-	-	-	45,000	45,000	45,000	45,000	45,000	45,000	45,000	45,000	45,000
Total sales, EURm	-	-	-	-	111	168	225	338	454	513	573	633	694
Royalty rate, %	-	-	-	-	15%	15%	15%	15%	15%	15%	15%	15%	15%
Royalties to Cantargia, EURm	-	-	-	-	17	25	34	51	68	77	86	95	104
RoW													
Patient volume	-	-	-	-	-	-	1,800	4,544	11,014	13,905	14,044	14,185	14,327
Price, USD	-	-	-	-	-	-	35,000	35,000	35,000	35,000	35,000	35,000	35,000
Total sales, USDm	-	-	-	-	-	-	63	159	385	487	492	496	501
Royalty rate, %	-	-	-	-	-	-	15%	15%	15%	15%	15%	15%	15%
Royalties to Cantargia, USDm	-	-	-	-	-	-	9	24	58	73	74	74	75
Total													
Royalties to Cantargia, SEKm	-	-	-	-	281	424	651	1,065	1,652	1,935	2,092	2,252	2,413
Risk adjustment, %	-	-	-	-	35.2%	35.2%	35.2%	35.2%	35.2%	35.2%	35.2%	35.2%	35.2%
Total risk adjusted royalties, SEKm	-	-	-	-	99	149	229	375	581	681	736	792	849

Source: Nordea estimates


REVENUE MODEL, CAN04, PDAC

	2020E	2021E	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E	2031E	2032E
US													
Patient volume	-	-	-	-	891	1,343	1,799	2,260	2,726	2,968	3,212	3,228	3,244
Price, USD	-	-	-	-	70,000	70,000	70,000	70,000	70,000	70,000	70,000	70,000	70,000
Total sales, USDm	-	-	-	-	62	94	126	158	191	208	225	226	227
Royalty rate, %	-	-	-	-	15%	15%	15%	15%	15%	15%	15%	15%	15%
Royalties to Cantargia, USDm	-	-	-	-	9	14	19	24	29	31	34	34	34
Europe													
Patient volume	-	-	-	-	2,322	3,500	4,690	5,892	7,106	7,737	8,374	8,416	8,458
Price, EUR	-	-	-	-	45,000	45,000	45,000	45,000	45,000	45,000	45,000	45,000	45,000
Total sales, EURm	-	-	-	-	104	158	211	265	320	348	377	379	381
Royalty rate, %	-	-	-	-	15%	15%	15%	15%	15%	15%	15%	15%	15%
Royalties to Cantargia, EURm	-	-	-	-	16	24	32	40	48	52	57	57	57
RoW													
Patient volume	-	-	-	-	-	-	507	1,281	3,104	3,919	3,958	3,998	4,038
Price, USD	-	-	-	-	-	-	35,000	35,000	35,000	35,000	35,000	35,000	35,000
Total sales, USDm	-	-	-	-	-	-	18	45	109	137	139	140	141
Royalty rate, %	-	-	-	-	-	-	15%	15%	15%	15%	15%	15%	15%
Royalties to Cantargia, USDm	-	-	-	-	-	-	3	7	16	21	21	21	21
Total													
Royalties to Cantargia, SEKm	-	-	-	-	243	367	515	676	886	990	1,058	1,064	1,071
Risk adjustment, %	-	-	-	-	18.5%	18.5%	18.5%	18.5%	18.5%	18.5%	18.5%	18.5%	18.5%
Total risk adjusted royalties, SEKm	-	-	-	-	45	68	95	125	164	184	196	197	199

Source: Nordea estimates

For reference, our sales forecasts can be compared to the consensus (EvaluatePharma) sales forecasts for Canakinumab, which indicate risk-adjusted sales of over USD 1bn. No consensus data for Canakinumab is provided after 2026E.

CANAKINUMAB VERSUS CAN04, REVENUE FORECASTS (USDm)



Source: EvaluatePharma and Nordea estimates

By applying a WACC of 10-12% to our risk-adjusted revenues (including royalties, upfront payments and milestone payments), we derive a fair value range of SEK 48-54 per share. In our view, the next triggers are the upcoming ph IIa results for CANFOUR, expected in late 2020 and early 2021, and a potential partnership agreement. Prior to this, Novartis will likely publish its ph III results for Canakinumab, which will provide further insight into the potential in targeting the IL1-system for cancer treatment.

CANTARGIA: DETAILED ESTIMATES

	2019				2020				2018	2019	2020E	2021E	2022E
	Q1	Q2	Q3	Q4	Q1	Q2	Q3E	Q4E					
Income (incl. milestones)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2,850	0
Research and development costs	-20.6	-20.8	-23.2	-32.8	-36.1	-33.7	-47.5	-57.7	-51.7	-97.5	-175.0	-190	-53
Administrative costs	-2.8	-4.3	-2.6	-3.4	-3.4	-4.1	-3.5	-3.0	-15.8	-13.1	-14.0	-15	-15
Other operating expenses	-0.2	-0.1	-0.4	-0.3	-0.4	0.1	-0.4	-0.9	-0.5	-1.0	-1.6	0	0
EBIT	-23.7	-25.2	-26.3	-36.4	-39.9	-37.7	-51.4	-62	-93.3	-111.6	-190.5	2,645	-67
Net financials	0.1	0.2	0.3	0.2	0.0	0.6	0.6	0.4	2.1	0.8	1.6	5	36
Net income	-23.5	-25.0	-26.0	-36.3	-40.0	-37.1	-50.8	-61.1	-91.2	-110.8	-188.9	2,067	-24

Source: Company data and Nordea estimates

Reported numbers and forecasts

INCOME STATEMENT											
SEKm	2012	2013	2014	2015	2016	2017	2018	2019	2020E	2021E	2022E
Total revenue	0	0	0	0	0	0	0	0	0	2,850	0
Revenue growth	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.m.	-100.0%
of which organic	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
of which FX	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
EBITDA	0	0	0	-17	-45	-60	-93	-112	-191	2,645	-68
Depreciation and impairments PPE	0	0	0	0	0	0	0	0	0	0	0
of which leased assets	0	0	0	0	0	0	0	0	0	0	0
EBITA	0	0	0	-17	-45	-60	-93	-112	-191	2,645	-68
Amortisation and impairments	0	0	0	0	0	0	0	0	0	0	0
EBIT	0	0	0	-17	-45	-60	-93	-112	-191	2,645	-68
of which associates	0	0	0	0	0	0	0	0	0	0	0
Associates excluded from EBIT	0	0	0	0	0	0	0	0	0	0	0
Net financials	0	0	0	0	0	0	2	1	2	5	36
of which lease interest	0	0	0	0	0	0	0	0	0	0	0
Changes in value, net	0	0	0	0	0	0	0	0	0	0	0
Pre-tax profit	0	0	0	-17	-45	-60	-91	-111	-189	2,650	-32
Reported taxes	0	0	0	0	0	0	0	0	0	-583	7
Net profit from continued operations	0	0	0	-17	-45	-60	-91	-111	-189	2,067	-25
Discontinued operations	0	0	0	0	0	0	0	0	0	0	0
Minority interests	0	0	0	0	0	0	0	0	0	0	0
Net profit to equity	0	0	0	-17	-45	-60	-91	-111	-189	2,067	-25
EPS, SEK	n.a.	n.a.	n.a.	-1.28	-2.14	-1.28	-1.38	-1.52	-2.08	22.72	-0.27
DPS, SEK	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
of which ordinary	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
of which extraordinary	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Profit margin in percent											
EBITDA	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	92.8%	n.m.
EBITA	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	92.8%	n.m.
EBIT	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	92.8%	n.m.
Adjusted earnings											
EBITDA (adj)	0	0	0	-17	-45	-60	-93	-112	-191	2,645	-68
EBITA (adj)	0	0	0	-17	-45	-60	-93	-112	-191	2,645	-68
EBIT (adj)	0	0	0	-17	-45	-60	-93	-112	-191	2,645	-68
EPS (adj, SEK)	n.a.	n.a.	n.a.	-1.28	-2.14	-1.28	-1.38	-1.52	-2.08	22.72	-0.27
Adjusted profit margins in percent											
EBITDA (adj)	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	92.8%	n.m.
EBITA (adj)	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	92.8%	n.m.
EBIT (adj)	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	92.8%	n.m.
Performance metrics											
CAGR last 5 years											
Net revenue	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
EBITDA	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
EBIT	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
EPS	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.m.	n.m.	n.m.
DPS	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Average last 5 years											
Average EBIT margin	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	76.8%	76.5%
Average EBITDA margin	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	76.8%	76.5%
VALUATION RATIOS - ADJUSTED EARNINGS											
SEKm	2012	2013	2014	2015	2016	2017	2018	2019	2020E	2021E	2022E
P/E (adj)	n.a.	n.a.	n.a.	n.a.	n.a.	n.m.	n.m.	n.m.	n.m.	2.4	n.m.
EV/EBITDA (adj)	n.a.	n.a.	n.a.	n.a.	n.a.	n.m.	n.m.	n.m.	n.m.	0.9	n.m.
EV/EBITA (adj)	n.a.	n.a.	n.a.	n.a.	n.a.	n.m.	n.m.	n.m.	n.m.	0.9	n.m.
EV/EBIT (adj)	n.a.	n.a.	n.a.	n.a.	n.a.	n.m.	n.m.	n.m.	n.m.	0.9	n.m.
VALUATION RATIOS - REPORTED EARNINGS											
SEKm	2012	2013	2014	2015	2016	2017	2018	2019	2020E	2021E	2022E
P/E	n.a.	n.a.	n.a.	n.a.	n.a.	n.m.	n.m.	n.m.	n.m.	2.4	n.m.
EV/Sales	n.a.	n.a.	n.a.	n.a.	n.a.	n.m.	n.m.	n.m.	n.m.	0.86	n.m.
EV/EBITDA	n.a.	n.a.	n.a.	n.a.	n.a.	n.m.	n.m.	n.m.	n.m.	0.9	n.m.
EV/EBITA	n.a.	n.a.	n.a.	n.a.	n.a.	n.m.	n.m.	n.m.	n.m.	0.9	n.m.
EV/EBIT	n.a.	n.a.	n.a.	n.a.	n.a.	n.m.	n.m.	n.m.	n.m.	0.9	n.m.
Dividend yield (ord.)	n.a.	n.a.	n.a.	n.a.	n.a.	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
FCF yield	n.a.	n.a.	n.a.	n.a.	n.a.	-13.7%	-11.1%	-8.1%	-4.3%	42.5%	-0.5%
FCF Yield bef A&D, lease adj	n.a.	n.a.	n.a.	n.a.	n.a.	-13.7%	-11.1%	-7.6%	-4.3%	42.5%	-0.5%
Payout ratio	n.a.	n.a.	n.a.	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Source: Company data and Nordea estimates

BALANCE SHEET

SEKm	2012	2013	2014	2015	2016	2017	2018	2019	2020E	2021E	2022E
Intangible assets	1	2	2	0	0	0	0	0	7	7	7
of which R&D	1	2	2	0	0	0	0	0	0	0	0
of which other intangibles	0	0	0	0	0	0	0	0	7	7	7
of which goodwill	0	0	0	0	0	0	0	0	0	0	0
Tangible assets	0	0	0	0	0	0	0	7	7	7	7
of which leased assets	0	0	0	0	0	0	0	0	0	0	0
Shares associates	0	0	0	0	0	0	0	0	0	0	0
Interest bearing assets	0	0	0	0	0	0	0	0	0	0	0
Deferred tax assets	0	0	0	0	0	0	0	0	0	0	0
Other non-IB non-current assets	0	0	0	0	0	0	0	0	0	0	0
Other non-current assets	0	0	0	2	3	3	3	0	0	0	0
Total non-current assets	1	2	3	2	3	3	3	7	14	14	14
Inventory	0	0	0	0	0	0	0	0	0	0	0
Accounts receivable	0	0	0	0	0	0	0	1	12	20	15
Short-term leased assets	0	0	0	0	0	0	0	0	0	0	0
Other current assets	0	1	1	1	2	2	2	8	12	20	15
Cash and bank	3	1	17	25	35	270	167	150	349	2,416	2,392
Total current assets	3	2	17	25	37	271	168	159	373	2,456	2,422
Assets held for sale	0	0	0	0	0	0	0	0	0	0	0
Total assets	4	4	20	27	40	274	171	166	387	2,470	2,436
Shareholders equity	3	3	4	24	30	246	155	142	363	2,430	2,405
Of which preferred stocks	0	0	0	0	0	0	0	0	0	0	0
Of which equity part of hybrid debt	0	0	0	0	0	0	0	0	0	0	0
Minority interest	0	0	0	0	0	0	0	0	0	0	0
Total Equity	3	3	4	24	30	246	155	142	363	2,430	2,405
Deferred tax	0	0	0	0	0	0	0	0	0	0	0
Long term interest bearing debt	0	0	0	0	0	0	0	0	0	0	0
Pension provisions	0	0	0	0	0	0	0	0	0	0	0
Other long-term provisions	0	0	0	0	0	0	0	0	0	0	0
Other long-term liabilities	0	0	0	0	0	0	0	0	0	0	0
Non-current lease debt	0	0	0	0	0	0	0	0	0	0	0
Convertible debt	0	0	0	0	0	0	0	0	0	0	0
Shareholder debt	0	0	0	0	0	0	0	0	0	0	0
Hybrid debt	0	0	0	0	0	0	0	0	0	0	0
Total non-current liabilities	0	0	0	0	0	0	0	0	0	0	0
Short-term provisions	0	0	0	0	0	0	0	0	0	0	0
Accounts payable	0	1	1	2	7	21	9	13	12	20	15
Current lease debt	0	0	0	0	0	0	0	0	0	0	0
Other current liabilities	0	0	15	1	2	8	7	11	12	20	15
Short term interest bearing debt	0	0	0	0	0	0	0	0	0	0	0
Total current liabilities	1	1	16	3	10	28	16	24	24	40	30
Liabilities for assets held for sale	0	0	0	0	0	0	0	0	0	0	0
Total liabilities and equity	4	4	20	27	40	274	171	166	387	2,470	2,436
Balance sheet and debt metrics											
Net debt	-3	-1	-17	-25	-35	-270	-167	-150	-349	-2,416	-2,392
of which lease debt	0	0	0	0	0	0	0	0	0	0	0
Working capital	0	0	-15	-2	-7	-27	-15	-14	0	0	0
Invested capital	0	2	-13	-1	-5	-24	-12	-8	14	14	14
Capital employed	3	3	4	24	30	246	155	142	363	2,430	2,405
ROE	0.0%	0.0%	0.0%	n.m.	n.m.	-43.6%	-45.4%	-74.5%	-74.8%	n.m.	-1.0%
ROIC	0.0%	0.0%	0.0%	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
ROCE	0.0%	0.0%	0.0%	n.m.	n.m.	-43.4%	-45.4%	-74.5%	-74.6%	n.m.	-1.3%
Net debt/EBITDA	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	-0.9	n.m.
Interest coverage	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Equity ratio	81.5%	78.5%	20.4%	88.3%	75.6%	89.7%	90.4%	85.7%	93.8%	98.4%	98.8%
Net gearing	-86.2%	-47.8%	-406.6%	-103.1%	-116.0%	-109.6%	-107.6%	-105.4%	-96.2%	-99.4%	-99.4%

Source: Company data and Nordea estimates

CASH FLOW STATEMENT

SEKm	2012	2013	2014	2015	2016	2017	2018	2019	2020E	2021E	2022E
EBITDA (adj) for associates	0	0	0	-17	-45	-60	-93	-112	-191	2,645	-68
Paid taxes	0	0	0	0	0	0	0	0	0	-583	7
Net financials	0	0	0	0	0	0	0	1	2	5	36
Change in provisions	0	0	0	0	0	0	0	0	0	0	0
Change in other LT non-IB	0	0	0	-1	-1	0	0	3	0	0	0
Cash flow to/from associates	0	0	0	0	0	0	0	0	0	0	0
Dividends paid to minorities	0	0	0	0	0	0	0	0	0	0	0
Other adj to reconcile to cash flow	0	-8	-8	1	-2	0	0	-3	0	0	0
Funds from operations (FFO)	0	-8	-8	-17	-47	-60	-93	-111	-189	2,067	-25
Change in NWC	0	0	15	-13	5	19	-12	0	-14	0	0
Cash flow from operations (CFO)	0	-8	7	-30	-42	-41	-105	-111	-203	2,067	-25
Capital expenditure	0	0	0	0	0	0	0	0	-7	0	0
Free cash flow before A&D	0	-8	7	-30	-42	-41	-105	-111	-210	2,067	-25
Proceeds from sale of assets	0	0	0	0	0	0	0	0	0	0	0
Acquisitions	0	0	0	0	0	0	0	-7	0	0	0
Free cash flow	0	-8	7	-30	-42	-41	-105	-118	-210	2,067	-25
Free cash flow bef A&D, lease adj	0	-8	7	-30	-42	-41	-105	-111	-210	2,067	-25
Dividends paid	0	0	0	0	0	0	0	0	0	0	0
Equity issues / buybacks	0	8	10	45	56	304	0	98	410	0	0
Net change in debt	0	0	0	0	0	0	0	-17	0	0	0
Other financing adjustments	0	0	0	0	0	0	30	0	0	0	0
Other non-cash adjustments	3	-1	-1	-7	-4	-28	-28	20	0	0	0
Change in cash	3	-1	15	8	10	235	-103	-17	199	2,067	-25
Cash flow metrics											
Capex/D&A	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Capex/Sales	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	0.0%	0.0%
Key information											
Share price year end (/current)	n.a.	n.a.	n.a.	n.a.	n.a.	6	14	20	53	53	53
Market cap.	n.a.	n.a.	n.a.	n.a.	n.a.	300	940	1,467	4,860	4,860	4,860
Enterprise value	n.a.	n.a.	n.a.	n.a.	n.a.	31	773	1,317	4,511	2,443	2,468
Diluted no. of shares, year-end (m)	0.0	0.0	0.0	13.5	20.9	46.9	66.2	72.8	91.0	91.0	91.0

Source: Company data and Nordea estimates

Disclaimer and legal disclosures

Origin of the report

This publication or report originates from: Nordea Bank Abp, including its branches Nordea Danmark, Filial af Nordea Bank Abp, Finland, Nordea Bank Abp, filial i Norge and Nordea Bank Abp, filial i Sverige (together "Nordea") acting through their unit Nordea Markets.

Nordea Bank Abp is supervised by the European Central Bank and the Finnish Financial Supervisory Authority and the branches are supervised by the European Central Bank and the Finnish Financial Supervisory Authority and the Financial Supervisory Authorities in their respective countries.

Content of report

This report has been prepared solely by Nordea Markets.

Opinions or suggestions from Nordea Markets credit and equity research may deviate from one another or from opinions presented by other departments in Nordea. This may typically be the result of differing time horizons, methodologies, contexts or other factors.

The information provided herein is not intended to constitute and does not constitute investment advice nor is the information intended as an offer or solicitation for the purchase or sale of any financial instrument. The information contained herein has no regard to the specific investment objectives, the financial situation or particular needs of any particular recipient. Relevant and specific professional advice should always be obtained before making any investment or credit decision.

Opinions or ratings are based on one or more methods of valuation, for instance cash flow analysis, use of multiples, behavioural technical analyses of underlying market movements in combination with considerations of the market situation and the time horizon. Key assumptions of forecasts or ratings in research cited or reproduced appear in the research material from the named sources. The date of publication appears from the research material cited or reproduced. Opinions and estimates may be updated in subsequent versions of the report, provided that the relevant company/issuer is treated anew in such later versions of the report.

Validity of the report

All opinions and estimates in this report are, regardless of source, given in good faith, and may only be valid as of the stated date of this report and are subject to change without notice.

No individual investment or tax advice

The report is intended only to provide general and preliminary information to investors and shall not be construed as the basis for any investment decision. This report has been prepared by Nordea Markets as general information for private use of investors to whom the report has been distributed, but it is not intended as a personal recommendation of particular financial instruments or strategies and thus it does not provide individually tailored investment advice, and does not take into account the individual investor's particular financial situation, existing holdings or liabilities, investment knowledge and experience, investment objective and horizon or risk profile and preferences. The investor must particularly ensure the suitability of an investment as regards his/her financial and fiscal situation and investment objectives. The investor bears the risk of losses in connection with an investment.

Before acting on any information in this report, it is recommendable to consult (without being limited to) one's financial, legal, tax, accounting, or regulatory advisor in any relevant jurisdiction.

The information contained in this report does not constitute advice on the tax consequences of making any particular investment decision. Each investor shall make his/her own appraisal of the tax and other financial merits of his/her investment.

Sources

This report may be based on or contain information, such as opinions, estimates and valuations which emanate from: Nordea Markets' analysts or representatives, publicly available information, information from other units of Nordea, or other named sources.

To the extent this publication or report is based on or contain information emanating from other sources ("Other Sources") than Nordea Markets ("External Information"), Nordea Markets has deemed the Other Sources to be reliable but neither Nordea, others associated or affiliated with Nordea nor any other person, do guarantee the accuracy, adequacy or completeness of the External Information.

Limitation of liability

Nordea or other associated and affiliated companies assume no liability as regards to any investment, divestment or retention decision taken by the investor on the basis of this report. In no event will Nordea or other associated and affiliated companies be liable for direct, indirect or incidental, special or consequential damages (regardless of whether being considered as foreseeable or not) resulting from the information in this report.

Risk information

The risk of investing in certain financial instruments, including those mentioned in this report, is generally high, as their market value is exposed to a lot of different factors such as the operational and financial conditions of the relevant company, growth prospects, change in interest rates, the economic and political environment, foreign exchange rates, shifts in market sentiments etc. Where an investment or security is denominated in a different currency to the investor's currency of reference, changes in rates of exchange may have an adverse effect on the value, price or income of or from that investment to the investor. Past performance is not a guide to future performance. Estimates of future performance are based on assumptions that may not be realized. When investing in individual shares, the investor may lose all or part of the investments.

Conflicts of interest

Readers of this document should note that Nordea Markets has received remuneration from the company mentioned in this document for the production of the report. The remuneration is not dependent on the content of the report.

Nordea, affiliates or staff in Nordea, may perform services for, solicit business from, hold long or short positions in, or otherwise be interested in the investments (including derivatives) of any company mentioned in the report.

To limit possible conflicts of interest and counter the abuse of inside knowledge, the analysts of Nordea Markets are subject to internal rules on sound ethical conduct, the management of inside information, handling of unpublished research material, contact with other units of Nordea and personal account dealing. The internal rules have been prepared in accordance with applicable legislation and relevant industry standards. The object of the internal rules is for example to ensure that no analyst will abuse or cause others to abuse confidential information. It is the policy of Nordea Markets that no link exists between revenues from capital markets activities and individual analyst remuneration. Nordea and the branches are members of national stockbrokers' associations in each of the countries in which Nordea has head offices. Internal rules have been developed in accordance with recommendations issued by the stockbrokers associations. This material has been prepared following the Nordea Conflict of Interest Policy, which may be viewed at www.nordea.com/mifid.

Distribution restrictions

The securities referred to in this report may not be eligible for sale in some jurisdictions. This report is not intended for, and must not be distributed to private customers in the UK or the US. This research report is intended only for, and may be distributed only to, accredited investors, expert investors or institutional investors in Singapore who may contact Nordea Bank, Singapore Branch of 138 Market Street, #09-01 CapitaGreen, Singapore 048946.

This publication or report may be distributed by Nordea Bank Abp Singapore Branch, which is subject to the supervision of the European Central Bank, the Finnish Financial Supervisory Authority and the Monetary Authority of Singapore.

This publication or report may be distributed in the UK to institutional investors by Nordea Bank Abp London Branch of 6th Floor, 5 Aldermanbury Square, London, EC2V 7AZ, which is under supervision of the European Central Bank, Finanssivalvonta (Financial Supervisory Authority) in Finland and subject to limited regulation by the Financial Conduct Authority and Prudential Regulation Authority in the United Kingdom. Details about the extent of our regulation by the Financial Conduct Authority and Prudential Regulation Authority are available from us on request.

This report may not be mechanically duplicated, photocopied or otherwise reproduced, in full or in part, under applicable copyright laws.

Analyst Shareholding

Nordea Markets analysts do not hold shares in the companies that they cover. No holdings or other affiliations by analysts or associates.

Fair value and sensitivity

We calculate our fair values by weighting DCF, DDM, SOTP, asset-based and other standard valuation methods. Our fair values are sensitive to changes in valuation assumptions, of which growth, margins, tax rates, working capital ratios, investment-to-sales ratios and cost of capital are typically the most sensitive. It should be noted that our fair values would change by a disproportionate factor if changes are made to any or all valuation assumptions, owing to the non-linear nature of the standard valuation models applied (mentioned above). As a consequence of the standard valuation models we apply, changes of 1-2 percentage points in any single valuation assumption can change the derived fair value by as much as 30% or more. All research is produced on an ad hoc basis and will be updated when the circumstances require it.

Marketing Material

This research report should be considered marketing material, as it has been commissioned and paid for by the subject company, and has not been prepared in accordance with the regulations designed to promote the independence of investment research and it is not subject to any legal prohibition on dealing ahead of the dissemination of the report. However, Nordea Markets analysts are according to internal policies not allowed to hold shares in the companies/sectors that they cover.

Market-making obligations and other significant financial interest

Nordea Markets has no market-making obligations in Cantargia.

Investment banking transactions

In view of Nordea's position in its markets readers should assume that the bank may currently or may in the coming three months and beyond be providing or seeking to provide confidential investment banking services to the company/companies

Issuer Review

This report has not been reviewed by the Issuer prior to publication.

Completion Date

13 Oct 2020, 20:35 CET

Nordea Bank Abp	Nordea Bank Abp, filial i Sverige	Nordea Danmark, Filial af Nordea Bank Abp, Finland	Nordea Bank Abp, filial i Norge
Nordea Markets Division, Research Visiting address: Aleksis Kiven katu 7, Helsinki FI-00020 Nordea Finland	Nordea Markets Division, Research Visiting address: Smålandsgatan 17 SE-105 71 Stockholm Sweden	Nordea Markets Division, Research Visiting address: Grønjordsvej 10 DK-2300 Copenhagen S Denmark	Nordea Markets Division, Research Visiting address: Essendropsgate 7 N-0107 Oslo Norway
Tel: +358 9 1651 Fax: +358 9 165 59710	Tel: +46 8 614 7000 Fax: +46 8 534 911 60	Tel: +45 3333 3333 Fax: +45 3333 1520	Tel: +47 2248 5000 Fax: +47 2256 8650
Reg.no. 2858394-9 Satamaradankatu 5 Helsinki			